{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:24:10Z","timestamp":1790648650255,"version":"4.1.0"},"reference-count":22,"publisher":"S. Karger AG","issue":"Suppl. 1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2015]]},"abstract":"<jats:p>Mogamulizumab (KW-0761) is a humanized anti-CCR4 monoclonal antibody with a defucosylated Fc region (Potelligent\u00ae Technology), which markedly enhances antibody-dependent cellular cytotoxicity by increasing its binding affinity to the Fc&amp;#947; receptor expressed on effector cells. It is an effective agent for patients with CCR4-positive adult T-cell leukemia and peripheral T-cell lymphoma, for which no standard therapy exists, and it has an acceptable toxicity profile. In addition, because CCR4 is expressed on CD45RA&lt;sup&gt;-&lt;\/sup&gt;FOXP3&lt;sup&gt;high&lt;\/sup&gt;CD4&lt;sup&gt;+&lt;\/sup&gt; effector regulatory T (Treg) cells, it is an even more attractive target, because Treg cells involved in the tumor escape from host immunity in the tumor microenvironment. Based on this concept, we conducted a clinical study of mogamulizumab for the treatment of CCR4-negative advanced or recurrent solid cancer, with the aim of depleting effector Treg cells and thus boosting anti-cancer immune responses. In this study, mogamulizumab infusion at doses ranging from 0.1 to 1.0 mg\/kg was safe and well tolerated. Four of 10 patients showed stable disease during treatment and showed long-term survival. Mogamulizumab efficiently depleted effector Treg cells even at the lowest dose of 0.1 mg\/kg, and an augmentation or induction of specific immune responses to cancer\/testis antigens was observed in some patients. In the near future, a novel immunotherapy targeting Treg cells with mogamulizumab will be offered to patients with different types of cancer.<\/jats:p>","DOI":"10.1159\/000431059","type":"journal-article","created":{"date-parts":[[2015,11,9]],"date-time":"2015-11-09T22:01:22Z","timestamp":1447106482000},"page":"16-21","source":"Crossref","is-referenced-by-count":33,"title":["Clinical Application of Anti-CCR4 Monoclonal Antibody"],"prefix":"10.1159","volume":"89","author":[{"given":"Ryuzo","family":"Ueda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2015,11,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1413488"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/11.1.81"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0371"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2111"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2012.00322"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12617"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M210665200"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2068"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2697"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0983"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900699"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3575"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3472"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.0924"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13338"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.03.019"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1316796110"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01767.x"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2006.00307.x"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0357"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/431059","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/431059","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/431059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:10:07Z","timestamp":1745431807000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000431059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":22,"journal-issue":{"issue":"Suppl. 1","published-online":{"date-parts":[[2015,11,1]]},"published-print":{"date-parts":[[2015,11,10]]}},"URL":"https:\/\/doi.org\/10.1159\/000431059","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"value":"0030-2414","type":"print"},{"value":"1423-0232","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}